Target based Bispecific Antibody (BsAb) Design Services

Building upon its robust bispecific antibody development platforms, Creative Biolabs delivers tailored BsAb design solutions that harness a spectrum of cutting-edge methodologies to engineer antibodies precisely aligned with customer needs. Our extensive portfolio encompasses BsAbs aimed at various targets, including distinct epitopes, ligands, receptors, and immune cell markers, thereby enabling researchers to address a multitude of applications with precision and versatility.

Fig.1 Schematic diagram of BsAbs structure and function.^{1, 3}

BsAbs have rapidly emerged as vital therapeutic agents for a broad range of conditions, from cancer to inflammatory and autoimmune diseases. Their inherent dual specificity permits simultaneous modulation of separate signaling routes. With deep expertise in both design and production, Creative Biolabs is well positioned to provide first-class, innovative BsAbs that meet the rigorous demands of clinical and research settings.

BsAbs Targeting Different Epitopes

BsAbs can simultaneously engage multiple epitopes on a single antigen or distinct epitopes on different antigens, thereby enhancing functional avidity and amplifying neutralizing or activating effects. Given that numerous diseases stem from redundant or synergistic mediator actions, BsAbs offer the unique advantage of concurrently targeting two such entities to obstruct multiple pathological factors and pathways, thereby improving therapeutic outcomes. Creative Biolabs has advanced epitope mapping technologies, provides premium BsAbs engineered to effectively bind diverse epitopes, underscoring their commitment to advancing targeted therapies.

BsAbs Targeting Different Ligands

Ligands are typically defined as molecules that elicit intercellular or intracellular signaling upon engaging specific receptors. A variety of bispecific antibody formats, including scFv-IgG, diabodies, and scFv-HSA fusion proteins, have been engineered to target soluble ligands involved in signaling cascades. These targets span growth factors, regulators of angiogenesis and vasculogenesis, as well as proinflammatory mediators. Creative Biolabs provides superior BsAbs that effectively address a spectrum of ligand targets, thereby advancing the therapeutic modulation of key signaling pathways.

BsAbs Targeting Different Receptors

In biological and pharmacological contexts, receptors denote membrane-associated proteins that, upon ligand binding, transduce signals to orchestrate downstream intracellular or intercellular responses. These receptors are categorized by their membrane localization into cell surface, cytoplasmic, and nuclear classes. Creative Biolabs develops bespoke bispecific antibodies engineered to obstruct these receptor-mediated pathways, thereby offering targeted therapeutic strategies for disease management.

BsAbs Targeting Different Cells

In recent years, there has been a burgeoning interest in crafting BsAbs that harness immune effector cells to combat various tumors and immune disorders. Certain BsAbs are designed to redirect immune cells toward malignant targets, thereby inducing anti-tumor responses such as T cell-mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytosis. Multiple BsAb constructs that engage T cells, natural killer cells, and other Fc receptor-mediated effectors are currently progressing through clinical trials. Bispecific T cell engagers and BiKEs, which target NK cells, serve as prominent exemplars of this innovative therapeutic modality.

Published Data

Fig.2 Schematic illustration of four anti-EGFR × Anti-CD16 BsAbs with varying domain arrangements.^{2, 3}

Researchers developed and assessed a humanized bispecific diabody (bsDb) aimed at targeting EGFR and CD16 on NK cells (hEx16-Dbs). Given the impact of domain arrangement on the efficacy of a humanized bsDb, it is crucial to consider both the target antigen and the antibody's mode of action during the development of highly effective BsAbs. Ultimately, they identified a specific domain configuration that demonstrated enhanced cytotoxicity in growth inhibition assays. At Creative Biolabs, our target based bsab design service offers support in analyzing these structural challenges in BsAb design tailored to several specific targets.

Equipped with a multidisciplinary team, cutting-edge facilities, and decades of expertise in antibody engineering and production, Creative Biolabs is committed to delivering superior bispecific antibodies. The company further extends a comprehensive suite of services for BsAb development, reflecting its steadfast dedication to advancing biomedical innovation.